For the Three Months Ended June 30,

For the Six Months Ended June 30,

2026

2025

2026

2025

Net loss available to Class A common stockholders

$

(28,422

)

$

(16,552

)

$

(48,459

)

$

(33,286

)

(Increase)/Decrease in ProKidney Corp. accumulated deficit for impact of
   subsidiary equity-based compensation

1

722

147

1,539

(Increase)/Decrease in ProKidney Corp. additional paid-in capital for exchange
   of Common Units in PK Holdings for Class A common stock

(124,998

)

(2,834

)

(125,025

)

(5,252

)

(Increase)/Decrease in ProKidney Corp. additional paid-in capital for vesting of
   Restricted Common Units in PK Holdings

(37,516

)

(3,997

)

(40,031

)

(9,170

)

Change from net loss available to Class A common stockholders and change
   in ownership interest in PK Holdings

$

(190,935

)

$

(22,661

)

$

(213,368

)

$

(46,169

)